shares of omega diagnostics group plc rose 13 on monday after the company said that it has agreed to the sale of its cd4 business in line with the boards plan to focus on its highergrowth health  nutrition division the medical diagnostics company said it has selected a preferred bidder for the business which has been granted four weeks to complete the rest of its due diligence it added that completion of the sale is expected shortly after that whereupon a significant upfront cash payment will be made by the purchaser the company said the sale also includes a future royalty stream linked to visitect cd4 test sales without providing any figures shares at 0707 gmt were up 040 pence at 350 pence having withdrawn from the covid19 market and disposed of the alva site earlier this year the divestment of our lossmaking cd4 business will leave the group solely focused on our highermargin health  nutrition division chief executive jag grewal said the net proceeds from the sale of the cd4 business will enable our product and geographical expansion ambitions to be realized